Floatz logo

Therapeutic Asset Ratings

91,564 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Sonlicromanol
MELAS Syndrome
Khondrion BVP3BB (70)
Sonlicromanol
Mitochondrial Disease
Khondrion BVP3BB (70)
Stsp-0601 For
Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.P3BB (70)
Tacrolimus
Chronic Myeloid Leukemia
Stanford UniversityP3BB (70)
Tamoxifen
Breast Neoplasm
Eli Lilly and CompanyP3BB (70)
Tamoxifen
Male Breast Carcinoma
Jose Pablo LeoneP3BB (70)
Tebentafusp
Melanoma
Immunocore LtdP3BB (70)
Trastuzumab
Hormone Receptor-Positive Breast Cancer
Tianjin Medical University Cancer Institute and HospitalP3BB (70)
Trastuzumab
Metastatic Neoplasm
City of Hope Medical CenterP3BB (70)
Trastuzumab Duocarmazine
Breast Cancer
Byondis B.V.P3BB (70)
Vincristine Sulfate
Primary Mediastinal Large B-Cell Lymphoma
National Research Center for Hematology, RussiaP3BB (70)
Vincristine Sulfate
HIV Infectious Disease
City of Hope Medical CenterP3BB (70)
Vincristine Sulfate
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (70)
Vinorelbine Ditartrate
Lung Large Cell Carcinoma
AIO-Studien-gGmbHP3BB (70)
Xzp-3621
Non-Small Cell Lung Carcinoma
Xuanzhu Biopharmaceutical Co., Ltd.P3BB (70)
Zipalertinib
Non-Small Cell Lung Carcinoma
Jonsson Comprehensive Cancer CenterP3BB (70)
Zongertinib
Non-Small Cell Lung Carcinoma
Boehringer IngelheimP3BB (70)
Acalabrutinib
Follicular Lymphoma
Patrick C. Johnson, MDP2BB (70)
Adriamycin
Primary Effusion Lymphoma
National Cancer Institute (NCI)P2BB (70)
Anvumetostat
Non-Small Cell Lung Carcinoma
AmgenP2BB (70)
bay2757556
NTRK Fusion Positive Cancer
BayerP2BB (70)
Busulfanum
B-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow UniversityP2BB (70)
Capivasertib
Estrogen-Receptor Positive Breast Cancer
Imperial College LondonP2BB (70)
Carboplatin
Burkitt Lymphoma
New York Medical CollegeP2BB (70)
Carboplatin
Follicular Lymphoma
David Bond, MDP2BB (70)
Showing 1576 to 1600 of 42,327 assets
PreviousPage 64 of 1694Next